Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
GKOS's Cash-to-Debt is ranked higher than
82% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. GKOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GKOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 11.76 Max: No Debt
Current: No Debt
Equity-to-Asset 0.87
GKOS's Equity-to-Asset is ranked higher than
87% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. GKOS: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
GKOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.81  Med: 0.85 Max: 0.89
Current: 0.87
-5.81
0.89
Piotroski F-Score: 6
Altman Z-Score: 27.82
Beneish M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -1.56
GKOS's Operating Margin % is ranked lower than
62% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. GKOS: -1.56 )
Ranked among companies with meaningful Operating Margin % only.
GKOS' s Operating Margin % Range Over the Past 10 Years
Min: -67.78  Med: -21.63 Max: 3.71
Current: -1.56
-67.78
3.71
Net Margin % -0.64
GKOS's Net Margin % is ranked lower than
63% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. GKOS: -0.64 )
Ranked among companies with meaningful Net Margin % only.
GKOS' s Net Margin % Range Over the Past 10 Years
Min: -60.34  Med: -39.27 Max: 3.95
Current: -0.64
-60.34
3.95
ROE % -0.79
GKOS's ROE % is ranked lower than
62% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. GKOS: -0.79 )
Ranked among companies with meaningful ROE % only.
GKOS' s ROE % Range Over the Past 10 Years
Min: -0.79  Med: 4.26 Max: 4.26
Current: -0.79
-0.79
4.26
ROA % -0.69
GKOS's ROA % is ranked lower than
60% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. GKOS: -0.69 )
Ranked among companies with meaningful ROA % only.
GKOS' s ROA % Range Over the Past 10 Years
Min: -52.2  Med: -41.78 Max: 3.6
Current: -0.69
-52.2
3.6
ROC (Joel Greenblatt) % -14.48
GKOS's ROC (Joel Greenblatt) % is ranked lower than
68% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. GKOS: -14.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GKOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -760.88  Med: -526.13 Max: 45.47
Current: -14.48
-760.88
45.47
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GKOS's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

GKOS Guru Trades in Q4 2016

Ron Baron 530,365 sh (+360.14%)
Steven Cohen 364,300 sh (+155.47%)
Jim Simons 849,000 sh (+20.39%)
Paul Tudor Jones Sold Out
» More
Q1 2017

GKOS Guru Trades in Q1 2017

Caxton Associates 5,300 sh (New)
Jim Simons 1,206,200 sh (+42.07%)
Ron Baron 610,227 sh (+15.06%)
Steven Cohen 135,200 sh (-62.89%)
» More
Q2 2017

GKOS Guru Trades in Q2 2017

Steven Cohen 373,900 sh (+176.55%)
Ron Baron 1,072,246 sh (+75.71%)
Caxton Associates Sold Out
Jim Simons 640,700 sh (-46.88%)
» More
Q3 2017

GKOS Guru Trades in Q3 2017

Ron Baron 2,194,059 sh (+104.62%)
Steven Cohen Sold Out
Jim Simons 503,600 sh (-21.40%)
» More
» Details

Insider Trades

Latest Guru Trades with GKOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-09-30 Add 104.62%0.17%$31.26 - $42.82 $ 26.45-31%2,194,059
Ron Baron 2017-06-30 Add 75.71%0.1%$36.83 - $52.23 $ 26.45-39%1,072,246
Ron Baron 2017-03-31 Add 15.06%0.02%$33.61 - $51.3 $ 26.45-39%610,227
Ron Baron 2016-12-31 Add 360.14%0.08%$30.61 - $38.73 $ 26.45-23%530,365
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ATRI, ROCO:1565, NAS:OSUR, NAS:IRTC, XKLS:7153, SZSE:300595, SZSE:300061, TSE:3593, SZSE:300171, SZSE:300358, TSE:7730, LSE:AMS, NAS:LMNX, XKRX:048260, SZSE:300677, XMCE:FAE, SHSE:603987, TSE:7780, SHSE:603222, SZSE:002432 » details
Traded in other countries:6GJ.Germany,
Headquarter Location:USA
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Guru Investment Theses on Glaukos Corp

Baron Opportunity Fund Comments on Glaukos Corp - Apr 20, 2017

Shares of Glaukos Corporation (NYSE:GKOS), a pioneer of minimally-invasive products and procedures for the treatment of glaucoma, were up in the first quarter due to strong financial results that beat Street expectations, with revenues growing 64%. The company also raised 2017 guidance and announced favorable Medicare reimbursement. Glaukos’ products and procedures are currently approved for only a subset of the market. We believe the company will continue to deliver strong growth as its product coverage broadens. (Josh Riegelhaupt)



From the Baron Opportunity Fund first quarter 2017 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corporation - Jan 18, 2017

High growth These are higher risk/return companies typified by revenue growth of 20% or more that we believe will lead to dramatic earnings growth in the future. This category includes newer businesses with novel products or services. Yet these companies are not venture businesses. An example is Glaukos Corporation (NYSE:GKOS), a medical device company that sells a stent used to treat glaucoma, a disease that damages the optic nerve due to fluid buildup inside the eye. Glaukos’ first generation device, which is inserted into the eye during cataract surgery, has been proven to decrease intraocular pressure. Glaukos also has a promising product pipeline that includes next generation stents for stand-alone glaucoma procedures and an injectable drug delivery implant. The company has a two-year lead over its competitors, patent protection, and strong clinical data. We believe the addressable market exceeds $5 billion.





From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corp - Oct 25, 2016

Glaukos Corporation (NYSE:GKOS) is the current market leader in the field of minimally-invasive glaucoma surgery or MIGS. As a pioneer in the field, Glaukos was the first to obtain FDA approval and insurance reimbursement for their eye stent, which they cleverly branded the iStent. Given the progressive nature of glaucoma that inevitably leads to blindness unless one’s eye pressure is effectively controlled, the iStent offers ophthalmologists a paradigm-shifting treatment option. Effectively, the iStent is a micro-sized plumbing solution that clears a blocked drain enabling a return of proper fluid flow. This allows for continuous pressure control and, as an ancillary benefit, a reduction in the need for concomitant glaucoma eye drops.







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corporation - May 19, 2016

Shares of Glaukos Corporation (NYSE:GKOS) declined in the first quarter as a result of the massive correction in the biotech/pharma space. Glaukos, which manufactures stents to relieve glaucoma pressure, expects 26% to 30% growth in 2016, which we think will drive revenue to $90 millin to $93 million. While major label expansion to deliver Glaukos’ iStents without cataract surgery (current FDA approval) is still some years away, we retain conviction because of the growth opportunity presented by the rising incidence of glaucoma as a result of the aging U.S. population.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Glaukos Corp

Baron Opportunity Fund Comments on Glaukos Corp Guru stock highlight
Shares of Glaukos Corporation (NYSE:GKOS), a pioneer of minimally-invasive products and procedures for the treatment of glaucoma, were up in the first quarter due to strong financial results that beat Street expectations, with revenues growing 64%. The company also raised 2017 guidance and announced favorable Medicare reimbursement. Glaukos’ products and procedures are currently approved for only a subset of the market. We believe the company will continue to deliver strong growth as its product coverage broadens. (Josh Riegelhaupt) Read more...
Baron Funds Comments on Glaukos Corporation Guru stock highlight
High growth These are higher risk/return companies typified by revenue growth of 20% or more that we believe will lead to dramatic earnings growth in the future. This category includes newer businesses with novel products or services. Yet these companies are not venture businesses. An example is Glaukos Corporation (NYSE:GKOS), a medical device company that sells a stent used to treat glaucoma, a disease that damages the optic nerve due to fluid buildup inside the eye. Glaukos’ first generation device, which is inserted into the eye during cataract surgery, has been proven to decrease intraocular pressure. Glaukos also has a promising product pipeline that includes next generation stents for stand-alone glaucoma procedures and an injectable drug delivery implant. The company has a two-year lead over its competitors, patent protection, and strong clinical data. We believe the addressable market exceeds $5 billion. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 75.19
GKOS's Forward PE Ratio is ranked lower than
98% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. GKOS: 75.19 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.90
GKOS's PB Ratio is ranked lower than
87% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. GKOS: 6.90 )
Ranked among companies with meaningful PB Ratio only.
GKOS' s PB Ratio Range Over the Past 10 Years
Min: 5.19  Med: 9.67 Max: 14.34
Current: 6.9
5.19
14.34
PS Ratio 6.41
GKOS's PS Ratio is ranked lower than
82% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. GKOS: 6.41 )
Ranked among companies with meaningful PS Ratio only.
GKOS' s PS Ratio Range Over the Past 10 Years
Min: 1.97  Med: 9.58 Max: 15
Current: 6.41
1.97
15
Price-to-Free-Cash-Flow 93.16
GKOS's Price-to-Free-Cash-Flow is ranked lower than
96% of the 72 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.99 vs. GKOS: 93.16 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GKOS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 93.16  Med: 219.2 Max: 635.64
Current: 93.16
93.16
635.64
Price-to-Operating-Cash-Flow 57.35
GKOS's Price-to-Operating-Cash-Flow is ranked lower than
91% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. GKOS: 57.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GKOS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 57.35  Med: 112.39 Max: 329.81
Current: 57.35
57.35
329.81
EV-to-EBIT -343.50
GKOS's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. GKOS: -343.50 )
Ranked among companies with meaningful EV-to-EBIT only.
GKOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -1191.8  Med: -53.3 Max: 768.6
Current: -343.5
-1191.8
768.6
EV-to-EBITDA 277.01
GKOS's EV-to-EBITDA is ranked lower than
97% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. GKOS: 277.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
GKOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.2  Med: 171.15 Max: 506.4
Current: 277.01
-189.2
506.4
EV-to-Revenue 5.33
GKOS's EV-to-Revenue is ranked lower than
77% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. GKOS: 5.33 )
Ranked among companies with meaningful EV-to-Revenue only.
GKOS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 9.9 Max: 14.5
Current: 5.33
0.1
14.5
Current Ratio 6.93
GKOS's Current Ratio is ranked higher than
85% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. GKOS: 6.93 )
Ranked among companies with meaningful Current Ratio only.
GKOS' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 5.81 Max: 8.45
Current: 6.93
0.52
8.45
Quick Ratio 6.48
GKOS's Quick Ratio is ranked higher than
89% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. GKOS: 6.48 )
Ranked among companies with meaningful Quick Ratio only.
GKOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 5.53 Max: 7.94
Current: 6.48
0.41
7.94
Days Inventory 131.10
GKOS's Days Inventory is ranked higher than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. GKOS: 131.10 )
Ranked among companies with meaningful Days Inventory only.
GKOS' s Days Inventory Range Over the Past 10 Years
Min: 65.71  Med: 106.37 Max: 266.8
Current: 131.1
65.71
266.8
Days Sales Outstanding 41.03
GKOS's Days Sales Outstanding is ranked higher than
79% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. GKOS: 41.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
GKOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.43  Med: 44.43 Max: 50.4
Current: 41.03
38.43
50.4
Days Payable 61.17
GKOS's Days Payable is ranked higher than
82% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. GKOS: 61.17 )
Ranked among companies with meaningful Days Payable only.
GKOS' s Days Payable Range Over the Past 10 Years
Min: 61.17  Med: 103.67 Max: 480.19
Current: 61.17
61.17
480.19

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.33
GKOS's Price-to-Net-Cash is ranked higher than
58% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.35 vs. GKOS: 10.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GKOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.81  Med: 12.84 Max: 20.85
Current: 10.33
7.81
20.85
Price-to-Net-Current-Asset-Value 7.83
GKOS's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. GKOS: 7.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GKOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.31  Med: 10.46 Max: 16.13
Current: 7.83
6.31
16.13
Price-to-Tangible-Book 7.13
GKOS's Price-to-Tangible-Book is ranked lower than
78% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.82 vs. GKOS: 7.13 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GKOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.14  Med: 10.14 Max: 15.01
Current: 7.13
6.14
15.01
Price-to-Median-PS-Value 0.67
GKOS's Price-to-Median-PS-Value is ranked higher than
72% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. GKOS: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GKOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 0.99 Max: 1.56
Current: 0.67
0.22
1.56
Earnings Yield (Greenblatt) % -0.28
GKOS's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. GKOS: -0.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GKOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2812.2  Med: -0.2 Max: 952.5
Current: -0.28
-2812.2
952.5

More Statistics

Revenue (TTM) (Mil) $150.78
EPS (TTM) $ -0.04
Short Percentage of Float14.29%
52-Week Range $26.45 - 52.49
Shares Outstanding (Mil)34.57

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) 0.36
EPS without NRI ($) 0.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}